Shin Nippon Biomedical Laboratories Publishes Transcript of First-Half FY2027 Results and New Medium-Term Business Plan Briefing
PUBT · 1d ago
Share
Listen to the news
- Shin Nippon Biomedical Laboratories' first-half revenue and profit for the year ending March 2027 exceeded forecasts raised on Aug. 5, 2026.
- Revenue rose 19% to a first-half record JPY 17.56 billion, driven by contract research projects carried over from fiscal 2025.
- Operating profit increased JPY 1.5 billion, partly reflecting approximately JPY 700 million in translational research expenses deferred to the second half.
- The Nov. 10, 2026, earnings briefing drew 40 attendees, with management participants including the chairman and CEO, president and deputy president.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shin Nippon Biomedical Laboratories Ltd. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending